BNP Paribas Financial Markets
AVIR icon

BNP Paribas Financial Markets’s Atea Pharmaceuticals AVIR Stock Holding History

BNP Paribas Financial Markets’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$366K Sell
78,721
-77,670
-50% -$386K ﹤0.01% 3921
2026
Q1 		$841K Buy
156,391
+132,258
+548% +$607K ﹤0.01% 3259
2025
Q4 		$86.2K Buy
24,133
+4,220
+21% +$13.4K ﹤0.01% 4443
2025
Q3 		$57.7K Buy
19,913
+7,286
+58% +$24.9K ﹤0.01% 4535
2025
Q2 		$45.5K Sell
12,627
-71,734
-85% -$214K ﹤0.01% 4294
2025
Q1 		$252K Sell
84,361
-12,072
-13% -$37.7K ﹤0.01% 3583
2024
Q4 		$323K Buy
+96,433
New +$320K ﹤0.01% 3583

Other funds holding AVIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BNP Paribas Financial Markets's AVIR Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Atea Pharmaceuticals (AVIR) stake by 50% in Q2 2026, selling an estimated $386K and leaving 78,721 shares worth $366K. The position accounts for ﹤0.01% of the portfolio, ranked #3921.

BNP Paribas Financial Markets first reported a position in AVIR in Q4 2024 and has held it in 7 quarters since. The position peaked at $841K in Q1 2026. 116 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • BNP Paribas Financial Markets held 78,721 shares of Atea Pharmaceuticals worth $366K as of Q2 2026.
  • BNP Paribas Financial Markets sold 77,670 Atea Pharmaceuticals shares in Q2 2026, an estimated $386K.
  • Atea Pharmaceuticals made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3921 holding.
  • BNP Paribas Financial Markets first reported a position in Atea Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • BNP Paribas Financial Markets's Atea Pharmaceuticals position peaked at $841K in Q1 2026.
  • 116 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.